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Abstract
Background: One of the greatest challenges in cancer genomics is to distinguish driver mutations from passenger
mutations. Whereas recurrence is a hallmark of driver mutations, it is difficult to observe recurring noncoding
mutations owing to a limited amount of whole-genome sequenced samples. Hence, it is required to develop a
method to predict potentially recurrent mutations.
Results: In this work, we developed a random forest classifier that predicts regulatory mutations that may recur
based on the features of the mutations repeatedly appearing in a given cohort. With breast cancer as a model, we
profiled 35 quantitative features describing genetic and epigenetic signals at the mutation site, transcription factors
whose binding motif was disrupted by the mutation, and genes targeted by long-range chromatin interactions. A
true set of mutations for machine learning was generated by interrogating publicly available pan-cancer genomes
based on our statistical model of mutation recurrence. The performance of our random forest classifier was
evaluated by cross validations. The variable importance of each feature in the classification of mutations was
investigated. Our statistical recurrence model for the random forest classifier showed an area under the curve
(AUC) of ~0.78 in predicting recurrent mutations. Chromatin accessibility at the mutation sites, the distance from
the mutations to known cancer risk loci, and the role of the target genes in the regulatory or protein interaction
network were among the most important variables.
Conclusions: Our methods enable to characterize recurrent regulatory mutations using a limited number of
whole-genome samples, and based on the characterization, to predict potential driver mutations whose recurrence
is not found in the given samples but likely to be observed with additional samples.
Background
Previous cancer genome analyses were limited to protein-
coding regions, which covers less than two percent of the
human genome. These efforts successfully discovered a
number of critical oncogenes and tumor suppressors.
However, a large number of cases still remain inexplicable
with those genes. The vast majority of cancer mutations
are found in regions that are extraneous to protein func-
tion. These mutations in noncoding regions may act as
driving factors that perturb the regulation of gene
expression. The most critical criterion for identifying
driving mutations is their recurrence [1]. It can be more
complicated to characterize mutation recurrence in non-
coding regions than in protein-coding genes. In a recent
study [2], the significance of mutation recurrence at a
given locus in noncoding regions was calculated by a
probabilistic model based on the expected and observed
mutation rates.
Recent studies suggest that the genetic and epigenetic
features can determine the landscape of cancer muta-
tions [3–6]. For example, Schuster-Böckler et al. [3] pro-
filed a set of diverse genetic and epigenetic factors in
terms of their association with the chromosomal density
of cancer mutations. Polak et al. [6] found that cell-of-
origin chromatin features are a strong determinant of
the distribution of cancer mutations. These studies
suggest that a range of genetic and epigenetic factors
can be used to estimate the significance of cancer muta-
tions. A critical aspect of regulatory mutations that has
not been previously dealt with is their genes targeted by
enhancer-promoter interactions. The recent growth of
chromatin interactome data enables to characterize the
targets of noncoding regulatory mutations. In addition,
the transcription factors (TFs) whose binding is affected* Correspondence: jungkyoon@kaist.ac.kr
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need to be examined, because critical noncoding muta-
tions may act through altering the binding of tumori-
genic TFs. We sought to construct a classification
method that can predict functional noncoding mutations
based on the significance of mutation recurrence and a
wide range of related features. A total of 35 features
were collected and used for the training of our classifica-
tion model. Recurrence significance was assessed by test-
ing different sizes of target and background windows.
Saturation of cancer gene discovery may be achieved
with ~5000 samples per tumour type in addition to > 4700
exomes that are currently available [7]. Noncoding mu-
tation discovery probably requires more samples because
of a larger mutation target size. Millions of potential
regulatory sequences exist in mammalian genomes [8].
Unfortunately, only a small number of whole-genome
sequenced cancer samples have been made available.
Moreover, unlike protein-changing mutations, it is
complicated to identify functional noncoding variants
as distinguished from inconsequential variants. In a
previous work, machine learning was employed to
predict noncoding mutations that exert high regulatory
impacts through TF binding disruption [9]. These
prompted us to develop a machine learning method
that can learn the features of the mutations that are re-
current in a small-sized cancer cohort and then predict




The overall schematic workflow of this study is depicted
in Fig. 1. We obtained whole-genome pan-cancer som-
atic mutation calls from public resources and used
Fig. 1 The overall schematic workflow. The construction of the training set and the training of our random forest classifier that aims to predict
recurring mutations in breast cancer
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breast cancer somatic mutations to obtain the instances
of the training set for the classifier. We examined the
recurrence of each mutation among the pan-cancer
samples and also measured the statistical significance
of the recurrence level. The raw count or statistical
significance of recurrence was used to classify the mu-
tations into true and false sets. Of the breast cancer
mutations, we investigated those in potential regulatory
regions of protein-coding genes through enhancer-
promoter interactions. We profiled the genetic and
epigenetic features of the mutation sites and the
cancer-related or functional features of the target genes
mapped to the mutations. In addition, we examined the
features of the TFs whose binding sites were expected
to undergo motif gain or loss due to the mutations.
Based on these mutation-, gene-, and TF-related fea-
tures, we trained a random forest classifier to predict re-
curring mutations. We performed a 10-repeated 5-fold
cross validation (CV) and used the receiver operating
characteristic (ROC) curve to quantify the classification
performance. Random forest was employed because the
ensemble method usually shows higher performance in
multi-dimensional problem space as compared to con-
ventional methods such as support vector machine
(SVM). We compared the performance of SVM and arti-
ficial neural network (ANN) with that of random forest
(Additional file 1: Figure S1). In addition, we conducted
a leave-one-out-cross-validation (LOOCV). Through the
LOOCV, we predicted important mutations from a test
set including instances of only one sample and a training
set consisting of instances from the rest of the samples.
Performance evaluation of raw and significant
recurrence models
We trained a random forest classifier for a total of 24 sets
of true and false mutations based on the raw recurrence
and recurrence significance model. The first 12 sets were
based on the raw recurrence model. Raw recurrence was
calculated in the window of 5 bp, 10 bp, or 20 bp, and the
mutation was assigned to the true set if the recurrence
count was greater than a cutoff (≥2, ≥ 3, ≥ 4, or ≥ 5)
(Table 1). The other sets were generated based on the
recurrence significance model. Recurrence was first
obtained in the window of 5 bp, 10 bp, or 20 bp, and
then its statistical significance was computed based on
the background window of 1 kbp, 10 kbp, 100 kbp, or 1
Mbp (Table 2). The mutation was assigned to the true or
false set with the p-value cutoff of 5 × 10−6 for the recur-
rence significance model. The false sets were randomly
composed as a subset of non-recurrent mutations such
that they were three times the size of the true sets.
The sets of true and false mutations were cross-
validated using the random forest classifier based on 35
features (Additional file 2: Table S1). Prediction accuracy
was calculated by averaging 10 5-fold CVs. Then, we drew
an ROC curve of prediction accuracy and quantified the
performance of the classifier using the AUC (Tables 1 and
2). The AUC values of the 12 test sets from the raw recur-
rence model (Table 1) indicate that our classifiers were
trained properly when the raw recurrence count was 4 or
higher. In particular, the recurrence window of 10 bp
generally outperformed 5 bp or 20 bp. We considered the
statistical significance of recurrence to account for local
background mutation frequency. First, in order to com-
pare the significance model with the raw recurrence
method, the p-value threshold was adjusted to 5 × 10−6 to
render the number of mutations in the true set compar-
able to the size of the true set in the raw recurrence model
(100 ~ 200 mutations for raw recurrence ≥ 4). We per-
formed 10-repeated 5-fold CV for varying window size
(Table 2). As a result, we determined that the 10 bp
window was most suitable for the significance model. For
the 10 bp window, the highest AUC was achieved when
the background window was 1 Mbp or 100 kbp. However,
Table 1 Performance of recurrent mutation prediction: Raw recurrence model
Recurrence window Raw recurrence threshold Size of true set Average AUC Randomized AUC
20 bp ≥2 4473 0.57 0.50
≥3 866 0.64 0.50
≥4 216 0.73 0.51
≥5 94 0.74 0.47
10 bp ≥2 2795 0.58 0.50
≥3 466 0.67 0.50
≥4 114 0.75 0.50
≥5 43 0.77 0.52
5 bp ≥2 1893 0.61 0.52
≥3 292 0.68 0.47
≥4 61 0.78 0.58
≥5 21 0.65 0.51
Yang et al. BMC Bioinformatics  (2016) 17:492 Page 3 of 11
because smaller true sets generally resulted in better
AUCs, we further adjusted the p-value cutoff, and found
that the 10 kbp and 100 kbp background windows per-
formed better than the 1 Mbp window when the size of
the true set was comparable (Additional file 1: Figures
S2–S3). Therefore, the 10 kbp and 100 kbp windows were
considered as the best background size for the recurrence
significance model. Meanwhile, our classifiers trained
using randomized true/false labels showed the average
AUC of 0.43 ~ 0.58 (Tables 1 and 2).
Comparison of raw and significant recurrence model
As seen in Tables 1 and 2 and (Additional file 1: Figure
S4), the AUC of the recurrence significance model was
not explicitly superior to that of the raw recurrence
model. We speculated that the number of mutations in
the training set mattered because the AUC from smaller
true sets tended to be higher. In order to equalize the
numbers of true mutations in the training sets, we ad-
justed the p-value of the significance model. As a result,
for the significance model of 10 bp windows, the p-value
thresholds were set to 3 × 10−6 for 10 kbp and 5 × 10−6
for 100 kbp background windows. With these thresh-
olds, training sets with background windows of 10 kbp
and 100 kbp both resulted in 114 true mutations, which
was the same as ≥ 4 raw recurrence counts in 10 bp
windows (Table 1). Similarly, to match the significant re-
currence model with the raw recurrence model of ≥3
counts, we used the additional p-value cutoff of 3 × 10−4.
With this threshold, the numbers of the true mutations
that were filtered using 10 kbp and 100 kbp background
windows were 474 and 452, which were close to 466 for
≥3 recurrence counts in the raw recurrence model.
Using the adjusted p-value cutoffs, we compared the raw
recurrence model of 10 bp windows with two signifi-
cance models of 10 bp windows (10 kbp and 100 kbp
background windows) based on the ROC curve (Fig. 2).
As a result, the classifier showing the highest perform-
ance was from the significance model with the 10 bp
recurrence window, 100 kbp background window, and
p-value cutoff of 5 × 10−6 (red solid line in Fig. 2). This
particular classifier showed an AUC of 0.78.
Prediction on new or external samples
We employed an LOOCV to test the utility of our classi-
fier in predicting significant recurrent mutations in a
new cancer sample based on the features learned from
reference cohort samples. Our classifier was trained by
using mutations in 118 breast cancer samples and then
used to predict significant mutations in the one sample
left out from the training process. We observed the
proportion of the mutations that are truly recurrent
Table 2 Performance of recurrent mutation prediction: Significant recurrence model
Recurrence window Background window Size of true set Average AUC Randomized AUC
20 bp 1Mbp 210 0.71 0.51
100kbp 212 0.71 0.50
10kbp 238 0.70 0.53
1kbp 191 0.70 0.51
10 bp 1Mbp 114 0.78 0.55
100kbp 114 0.78 0.51
10kbp 133 0.76 0.46
1kbp 99 0.76 0.49
5 bp 1Mbp 201 0.72 0.48
100kbp 198 0.72 0.47
10kbp 181 0.72 0.47
1kbp 131 0.73 0.43
Fig. 2 ROC curves comparing the raw recurrence and significant
recurrence model
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according to the significance of the prediction result for
each mutation as measured by the number of positive
votes by 1000 decision trees in our random forest classi-
fier (Fig. 3). By a majority vote of the individual trees,
both the classifier trained with the raw recurrence model
(Fig. 3a-b) and the classifier trained with the significant
recurrence model (Fig. 3c-d) preferentially identified
mutations that were actually recurrent in terms of the
raw recurrence count (Fig. 3a and c) or the recurrence
p-value (Fig. 3b and d).
There were mutations that were actually recurrent but
not positively predicted. These may indicate inconse-
quential mutations that do not share the features of
functional regulatory mutations. On the contrary, there
were mutations that were positively predicted but not
actually recurrent (the right tails of the curves for the
non-recurrent mutations in Fig. 3). There is a possibility
that the recurrence of these mutations is not detected
because of limited sample size. To estimate the capabil-
ity of our method to predict mutations whose recurrence
can be revealed only by additional samples, we recalcu-
lated the recurrence of each mutation using external
datasets which were not used when training our classi-
fier. We observed that the top-voted mutations from our
random forest classifier were more likely to exhibit their
recurrence upon sample addition than most recurrent
mutations from the raw recurrence model or most sig-
nificant mutations from the significance model (Fig. 4a
and b). However, this pattern was not observed when we
used lung cancer instead of breast cancer as external
samples (Fig. 4c and d), in agreement with the fact that
our random forest predictor relied on the features of the
genome, epigenome and transcriptome of breast cancer.
In addition, the random forest classifier trained based on
the significance model with the background window size
of 10 kbp outperformed that based on the background
window of 100 kbp.
Measuring variable importance
Variable importance was measured by the Mean Decrease
Accuracy of random forest (Table 3). Among others, the
chromatin accessibility signals (DnaseSig) at the mutated
site in the cancer cells and cells-of-origin stood out as the
most important feature in both the raw recurrence and
significant recurrence model. Other important features
with high importance in both tests included the cancer
gene score (CGS) of target genes in the protein interac-
tome (InteractNet.CGS_L1 and InteractNet.CGS_L2),
the sum of the differentially gene expression scores be-
tween cancer and normal for the downstream genes of
the mutation target genes in the regulatory network
(RegNet.DEG_score), the distance between the mutation
Fig. 3 Proportion of positive votes by 1000 decision trees of the random forest. a-b Proportion of votes by the classifier trained with the raw
recurrence model (≥4) for mutations in the test samples. c-d Proportion of votes by the classifier trained with the significant recurrence model
(p-value < 5 × 10−6) for mutations in the test sample. a, c Voting for mutations having no (0), moderate (2 or 3) recurrence, or high (≥4) raw
recurrence. b, d Voting for mutations whose recurrence significance was low (p ≥ 0.01), moderate (5 × 10−6 ≤ p < 0.01), or high (p < 5 × 10−6)
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site and its nearest cancer risk locus (Distance.to.GWAS),
the H3K27me3 signals in the cancer cells, and the
H3K4me1 signals in the cells-of-origin.
Meanwhile, the H3K9me3 and H3K36me3 signals in the
cells-of-origin but not in the cancer cells stood out under
both recurrence models. In addition, the importance
measure for the H3K9me3 signals in the raw recurrence
model significantly differed from the significance model.
This may reflect the fact that heterochromatin has high
mutation rates due to the lack of DNA damage repair
activity. In contrast, the importance of H3K36me3 in the
significance model was remarkably higher than that in the
raw recurrence model. Biological implications of each var-
iable’s importance remain to be further investigated.
Conclusions
We applied machine-learning techniques to facilitate the
discovery of important mutations in cancer. Our ma-
chine leaning method was capable of processing multiple
features concertedly, enabling us to consider various
genetic and epigenetic factors that have direct or indirect
relevance to mutagenesis and tumorigenesis. Of par-
ticular importance and novelty, one of the factors that
turned out to be critical in the prediction processes was
the oncogenic relevance of mutation target genes. This
factor was made available by leveraging the data of
three-dimensional chromatin structure that provide
long-range interactions between promoters and en-
hancers. We considered the expression change of the
genes due to the linked mutation, their effects on
downstream genes in the regulatory network, and their
physical or functional interactions with known cancer
genes. An additional benefit of using the chromatin
interactome data was that we were able to filter muta-
tions residing in regulatory regions.
We observed that both the raw and significant recur-
rence models worked properly. We found a proper win-
dow size for recurrence identification to be 10 bp, with
which our classifier achieved the highest performance
under the significance model. Meanwhile, the back-
ground mutation rates calculated within a 100 kbp
window showed the best performance. In addition, we
proposed important features to consider when inferring
cancer-driving mutations. For example, the chromatin
accessibility signals showed particularly high explanatory
power. We also identified other features such as the
distance of the mutation site to known cancer risk loci
and several histone marks that signify regulatory activity.
As described above, our network-based scores for target
genes also played an important role in mutation classi-
fication. Overall, most of the identified features had
biological relevance.
Fig. 4 Number of mutations whose recurrence was revealed by sample addition. The top-voted mutations from the random forest trained
with the significant recurrence model (100 kbp or 10 kbp as the background window) were compared to the same number of the most highly
recurrent mutations based on the raw or significance model. a-b Recurrence recalculated in the window of (a) 10 bp and (b) 100 bp after the
addition of new breast cancer samples. c-d Recurrence recalculated in the window of (c) 10 bp and (d) 100 bp after the addition of lung
cancer samples
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Our method was able to find putative driver mutations
that show low or no recurrence in currently available
samples but may show recurrence when additional can-
cer samples are interrogated. Our analyses using external
additional samples propose that our machine learning
approach will make it possible to expand the catalog of
putative noncoding driver mutations until mutation dis-
coveries have reached saturation through large-scale
whole-genome analyses.
Methods
Dataset for mutation candidates
We obtained public whole-genome mutation call data
for 507 samples across 10 different cancer types [10]
and 2297 samples across 18 cancer types from The
Cancer Genome Atlas (TCGA) data portal. In order to
eliminate any residual germ line mutations, all sam-
ples were filtered by the 1000 genome variants [11].
We chose 119 breast cancer sample with 647,695
Table 3 Feature list and variable importance
Category Mean decrease accuracy (%)
p < 5 × 10−6 Recurrence≥ 4
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somatic mutations for the learning and evaluation of
our classifier.
Target gene mapping
To map noncoding mutations to their target genes, we
employed two datasets for enhancer-promoter pairs.
First, we connected the mutations to the genes by using
the integrated method for predicting enhancer targets
(IM-PET), which was used to predict putative EP pairs
across 12 cell types by characterizing multiple genomic
features [12]. For the mutations of breast cancer, we
used IM-PET for the MCF-7 cell line. Second, the muta-
tions not connected via the IM-PET were mapped to
their target genes by the DNase I hypersensitive site
(DHS) correlation map [13]. The DHS correlation map
was constructed by computing DHS tag density correla-
tions across 349 diverse cell types between all possible
proximal and distal DHS pairs within 500 kb. The muta-
tions were mapped to the gene that had the maximum
DHS correlation across all cell types.
TF mapping
The position weight matrices for TFs were downloaded
from the TRANSFAC database [14] available at http://
www.gene-regulation.com/. The TF binding motifs
within DHS regions were identified using the FIMO pro-
gram [15]. FIMO was run for the wild-type and mutated
sequence separately. Motif gain or loss was identified
when only the mutant and wild-type exceeded the p-value
threshold, respectively. When motif gain or loss was iden-
tified, the binding gene scores (Table 3) were obtained for
the corresponding TF. The diff_Log_Pval_FIMO binding
score was defined as the logarithmic difference in the
FIMO p-value between the wild-type and mutant se-
quences, the avg_Log_Pval_FIMO was calculated by aver-
aging minus log of the two p-values, and the
Gain_or_Loss was set to 1 (gain) or −1 (loss). On the con-
trary, when there was no motif change due to the muta-
tion, the most likely binding site (lowest FIMO p-value)
was identified within the entire DHS region containing
the mutation. In this case, the diff_Log_Pval_FIMO was
set to 0, the avg_Log_Pval_FIMO to the minus log of the
lowest FIMO p-value, and the Gain_or_Loss to 0 (indicat-
ing no change). The DHS regions were obtained from the
ENCODE’s uniformly processed DNase-seq peaks in the
MCF-7 cell line [16].
Gene expression change features
We computed the Differentially Expressed Gene (DEG)
score by quantifying the difference of gene expression
between cancer and normal samples as a learning fea-
ture of our random forest. For this, we obtained RNA
sequencing data for tumor and matched normal samples
from the TCGA data portal. The expression values were
assumed to follow a normal distribution. The p-value
was calculated by the Students’ t-test based on the hy-
pothesis that there was no difference between cancer
and normal. We defined the DEG score as the negative
common logarithm of the p-value as below:
DEGscore ¼ xxþ 1 ; wherex ¼ − log p‐valueof t‐testð Þ
In addition, RegNet.DEG_score was defined as the sum
of the expression changes of all genes regulated by the
target gene or TF mapped to the mutation. Here, we used
a previously constructed Bayesian regulatory network in
breast cancer [17]. We summed the DEG_score of all
downstream genes reachable within 3 hops from the mu-
tation target gene or TF in the regulatory network.
Network features
We also used the network-related features of the muta-
tion target gene and binding TF. Specifically, the cancer
gene score (CGS) was defined to measure the degree of
connections with tumor suppressors or oncogenes [1,
18] in the following networks: (1) an integrated physical
interaction network (Interactome), created by merging
the yeast-two-hybrid proteome-scale interactions [19],
literature-based protein-protein interactions [19], binary
interactions identified from Stitch-seq [20], and high-
quality protein interactome from the HINT database
[21], and (2) HumanNet [22], a probabilistic functional
network of human genes, constructed by a modified
Bayesian integration of 21 types of omics data from mul-
tiple organisms. InteractNet.CGS and HumanNet.CGS
were defined as the number of known cancer genes
interacting with the mutation target gene in the Interac-
tome and HumanNet. Additional suffixes _L1 and _L2
indicate the hop count 1 and 2 from the target gene to
the cancer gene, respectively.
Genetic signal features
For each mutation site, we considered three genetic fea-
tures: the distance to cancer risk loci, replication timing,
and evolutionary conservation score. To measure the
degree of relation with cancer risk loci, we calculated
the distance to the nearest cancer-related genome-wide
association study (GWAS) SNPs from each mutation
position. We obtained a total of 1002 SNPs for 45 dif-
ferent tumour types from the GWAS catalogue [23].
The replication timing was calculated using data from
the study conducted by Hansen et al. [24]. Raw reads
were downloaded for four cell-cycle fractions (G1B, S1, S4
and G2), averaged to 4 million reads each, and normalized
to percentage replication per nucleotide position. An
early-to-late ratio was calculated as (G1B + S1)/(S4 + G2).
We computed a conservation score at each mutation
position using phastCons [25], available at the UCSC
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GoldenPath genome resource, which assigned a conserva-
tion score based on a phylogenetic hidden Markov model
for the estimation of the probability that each nucleotide
belongs to a conserved element.
Epigenetic signal features
We collected several epigenetic signal features for the
MCF-7 cell line from the ENCODE project [16]: DNase-
seq signals and ChIP-seq signals for several important
histone marks – H3K27ac, H3K27me3, H3K36me3,
H3K4me3, and H3K9me3. We also collected epigenetic
data of the human normal breast cell line, HMEC, in-
cluding DNase-seq signals and ChIP-seq signals for his-
tone marks such as H3K27ac, H3K27me3, H3K36me3,
H3K4me1, H3K4me2, H3K4me3, H3K79me2, H3K9ac,
H3K9me3, and H4K20me1.
Raw and significant recurrence models
In the raw recurrence model, we mapped the pan-cancer
mutations in windows of various sizes (5 bp, 10 bp, and
20 bp) centered on the breast cancer mutations. The
number of overlapping mutations within a window was
used as the raw recurrence count. Meanwhile, in the sig-
nificance model, the statistical significance of the muta-
tion of interest was estimated based on the background
mutation rate in 1 kbp to 1 Mbp windows (Fig. 5). We
assumed that mutation density follows the Poisson dis-
tribution. Therefore, the Poisson variable estimates the
level of mutation occurrence expected when there is no
biological effect (i.e., when there is no recurrence). Mu-
tation occurrence is expected to increase in proportion
to the window size and background mutation rate.
Therefore, when w the size of the recurrence window
and p the background mutation rate per single base pair,
the approximate p-value was calculated as below:
P value recurrence of site is xð Þ
¼ P X ≥xð Þ; where X
e
Poisson wpð Þ:
In other words, the given recurrence level, x, is tested
against the Poisson distribution, from which the estimated
recurrence level, X, is drawn. We computed the p-values
for all recurrent mutations using an R package.
Random forest classifier and cross-validation
Mutations were classified into true or false training sets
based on their raw recurrence or statistical significance as
described in the previous session. In the training dataset,
the true sets were comprised of highly recurrent or signifi-
cant mutations and the false sets were composed as ran-
dom sets of non-recurrent mutations. The false sets were
three times the size of the true sets. Then, we trained a
random forest classifier consisting of 1000 decision trees
based on the features described above. We used the algo-
rithm implemented in the R package randomForest
(http://www.r-project.org/) [26, 27]. The classification
performance was evaluated by a 10-repeated 5-fold cross
validation. We trained classifiers using various sets of true
and false mutations differing by the recurrence window
size (5 bp, 10 bp, and 20 bp) and the statistical back-
ground window size (1 kbp, 10 kbp, 100 kbp, and 1 Mbp).
The trained models were then evaluated by the AUC of
the ROC curve. We then selected classifiers showing high
performance, and performed a further validation by
Fig. 5 Illustration of the raw recurrence and significant recurrence model. (Left dotted box) Raw recurrence represented as the orange bar is not
significant relative to the expected occurrence (green curve) as estimated from the background mutation rates. (Right dotted box) On the contrary,
mutation recurrence (orange bar with asterisk) is statistically significant considering a low probability of background mutation occurrence
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LOOCV with the selected parameters. The LOOCV
method used all the mutations from one sample as the
testing set and the mutations from the remaining samples
as the training set. The training set was created and proc-
essed in the same manner as 5-fold cross validation. We
observed the proportion of votes of each mutation in the
test set and analyzed with raw recurrence and recurrence
significance. In addition, the importance of all variables in
each classifier was measured as the Mean Decrease Accur-
acy defined in the randomForest R package. Specifically,
the importance of the nth variable was estimated by ran-
domly permuting all the values of the nth variable in the
training set for each classifier. Decreased accuracy corre-
lates with the importance of the given variable. The vari-
able of high importance could be considered as a feature
that many significant mutations share.
Validation using an external dataset
In order to estimate the prediction performance of our
random forest, we recalculated the recurrence of the
positively predicted mutations after adding whole-genome
cancer samples that were not included in the training.
Specifically, for the top-voted mutations in our random
forest prediction, we checked whether there are additional
mutations in the new samples within the recurrence
window. Recurrent mutations were selected by their raw
recurrence, recurrence significance, and proportion of
votes by two random forest classifiers built with the
LOOCV. The two classifiers were built based on the
mutations from the significance model with the 10 bp
window, p-value cutoff of 5 × 10−6, and background win-
dow of two different sizes (10 kbp and 100 kbp). Using the
raw recurrence model, we selected 114, 466, and 2795 re-
current mutations with the threshold counts of ≥ 4, ≥ 3,
and ≥ 2, respectively. Then, we matched them with the
same numbers of most significant mutations from the
significance model and top-voted mutations from the
random forest classifiers (Fig. 5). Recurrence levels were
recalculated with new breast or lung cancer samples by
examining the numbers of mutations in the window of
10 bp or 100 bp centered on the mutation of interest.
Variant calls for the external cancer samples, composed of
92 breast and 90 lung cancer cases, were downloaded
from the TCGA portal.
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Additional file 1: Figure S1. Performance comparison between random
forest (RF), support vector machine (SVM) and artificial neural network (ANN).
Figure S2 Performance comparison for various sizes of recurrence window
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recurrence and background window sizes. Figure S4 Comparison of the raw
recurrence model and significant recurrence model. (PDF 771 kb)
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